• Intravacc and SynphaBase Announce Strategic Partnership to Advance Conjugate Vaccine Development

  • Intravacc and SynphaBase Announce Strategic Partnership to Advance Conjugate Vaccine Development

  • Intravacc and SynphaBase Announce Strategic Partnership to Advance Conjugate Vaccine Development

We Make Bioorganic
Chemistry Happen

We Make Bioorganic
Chemistry Happen

Rooted in glycochemistry, we deliver custom synthesis of complex molecules across glycans, peptides, RNA, and conjugates.

Rooted in glycochemistry, we deliver custom synthesis of complex molecules across glycans, peptides, RNA, and conjugates.

Contact us

Areas of Expertise

With glycochemistry at our core, we make difficult chemistry work.

Glycans & Carbohydrate Derivatives

  • Glycosylations & protecting group strategies

  • Modified sugars (L-, deoxy-, azido-)

  • Oligosaccharides & glycoconjugates

RNA & Nucleotide Building Blocks

  • RNA building blocks & modified nucleotides

  • siRNA & oligonucleotide constructs

  • Enzyme substrates & derivatives

Peptides & Amino Acid Derivatives

  • Unnatural amino acids

  • Peptides

  • Functionalized Derivatives

Conjugates & Linker Systems

  • Protein & antibody conjugation linkers

  • Glyco-, peptido- and hybrid systems

  • Amphiphilic molecules

Glycans & Carbohydrate Derivatives

  • Glycosylations & protecting group strategies

  • Modified sugars (L-, deoxy-, azido-)

  • Oligosaccharides & glycoconjugates

Peptides & Amino Acid Derivatives

  • Unnatural amino acids

  • Peptides

  • Functionalized Derivatives

RNA & Nucleotide Building Blocks

  • RNA building blocks & modified nucleotides

  • siRNA & oligonucleotide constructs

  • Enzyme substrates & derivatives

Conjugates & Linker Systems

  • Protein & antibody conjugation linkers

  • Glyco-, peptido- and hybrid systems

  • Amphiphilic molecules

Contact us

How We Support Your Project

Focused on challenging synthesis, from route design to reliable material.

Route Design

Designing viable synthesis routes for difficult target molecules.

  • Development of strategies for complex molecules

  • Resolution of bottlenecks and dead ends in existing routes

  • Early assessment of feasibility and scalability

  • Fast iteration toward a reliable working route

Process Optimization

Making difficult reactions work reliably at laboratory scale.

  • Improvement of yield, selectivity, and reproducibility

  • Identification and control of side reactions and impurities

  • Development of robust reaction and purification conditions

  • Preparation of processes suitable for production

Material Supply

Supply of small-scale quantities based on developed processes.

  • Manufacturing from milligram to multi-kilogram scale

  • Reference materials for analytical characterization

  • Non-GMP and small-scale GMP in-house capabilities

  • Tech transfer support for large-scale manufacturing

Route Design

Designing viable synthesis routes for difficult target molecules.

  • Development of strategies for complex molecules

  • Resolution of bottlenecks and dead ends in existing routes

  • Early assessment of feasibility and scalability

  • Fast iteration toward a reliable working route

Process Optimization

Making difficult reactions work reliably at laboratory scale.

  • Improvement of yield, selectivity, and reproducibility

  • Identification and control of side reactions and impurities

  • Development of robust reaction and purification conditions

  • Preparation of processes suitable for production

Material Supply

Supply of small-scale quantities based on developed processes.

  • Manufacturing from milligram to multi-kilogram scale

  • Reference materials for analytical characterization

  • Non-GMP and small-scale GMP in-house capabilities

  • Tech transfer support for large-scale manufacturing

Contact us

Technical Capabilities

In-house development across the scale, from discovery to production.

Synthesis & Scale Range

  • 250 mL to 160 L reaction scale

  • Low-temperature chemistry down to –60 °C

  • Parallel setups for rapid route iteration

  • Hydrogenation and specialized reactions in-house

  • Conditions designed for reproducible and robust scale-up

  • OligoPilot 100 for solid phase-synthesis

Analytical & Process Insight

  • GMP-qualified NMR (1H, 13C, 19F, 31P)

  • LC-MS for reaction monitoring and profiling

  • HPLC-UV/MS and CAD purity analysis

  • Identification of side products

  • Karl-Fischer

  • GMP-qualified NMR (1H, 13C, 19F, 31P)

  • LC-MS for reaction monitoring and profiling

  • HPLC-UV/MS and CAD purity analysis

  • Identification of side products

  • Karl-Fischer

Purification & Isolation

  • Chromatography up to 20 kg silica

  • Prep HPLC, MPLC, and flash systems

  • Lyophilization for sensitive compound isolation

  • Expertise in polar and complex molecules

  • Purification aligned with scale-up requirements

  • Crystallization screening (Crystal16)

Scale-Up & Tech Transfer

  • Internal scale-up and scalability approval

  • Development of robust procedures

  • Processes designed for scalability from start

  • Potential tech transfer to external manufacturing

  • Multi-100 kg production via external network

Synthesis & Scale Range

  • 250 mL to 160 L reaction scale

  • Low-temperature chemistry down to –60 °C

  • Parallel setups for rapid route iteration

  • Hydrogenation and specialized reactions in-house

  • Conditions designed for reproducible and robust scale-up

  • OligoPilot 100 for solid phase-synthesis

Purification & Isolation

  • Chromatography up to 20 kg silica

  • Prep HPLC, MPLC, and flash systems

  • Lyophilization for sensitive compound isolation

  • Expertise in polar and complex molecules

  • Purification aligned with scale-up requirements

  • Crystallization screening (Crystal16)

Analytical & Process Insight

  • GMP-qualified NMR (1H, 13C, 19F, 31P)

  • LC-MS for reaction monitoring and profiling

  • HPLC-UV/MS and CAD purity analysis

  • Identification of side products

  • Karl-Fischer

Scale-Up & Tech Transfer

  • Internal scale-up and scalability approval

  • Development of robust procedures

  • Processes designed for scalability from start

  • Potential tech transfer to external manufacturing

  • Multi-100 kg production via external network

Contact us

Quality and Regulatory Compliance

GMP Manufacturing for Early Clinical Supply

We provide GMP-grade material at multi-gram scale for active pharmaceutical ingredients, supporting early clinical phases (I/II) in full compliance with ICH Q7 (Chapter 19).

Dedicated GMP Laboratory Infrastructure

Our GMP laboratory enables controlled synthesis, purification, and final product isolation — including advanced chromatography, lyophilization, and compliant sampling procedures.

Regulatory Oversight and Inspection

Regular inspections by Swissmedic and ongoing client audits ensure consistent adherence to regulatory requirements and reinforce confidence in data integrity and product quality.

Certified Quality Management System

Our operations are aligned with ISO 9001, ensuring structured, traceable, and continuously monitored processes across all projects.

Contact us

About us

Dr. Arthur Bodenmüller

CEO & Founder

"Founded in 2000, SynphaBase has grown from an academic spin-off into a trusted Swiss CDRO specializing in complex carbohydrate synthesis. With deep roots in glycoscience and over 2,000 successful projects, we support pharmaceutical innovators from route scouting to late-stage clinical supply.

Our strength lies in combining high-purity synthesis with expert process development — always guided by precision, flexibility, and quality. ISO 9001 certified and Swissmedic compliant, we deliver value-based solutions that scale, adapt, and accelerate your path to market."

Dr. Arthur Bodenmüller

CEO & Founder

"Founded in 2000, SynphaBase has grown from an academic spin-off into a trusted Swiss CDRO specializing in complex carbohydrate synthesis. With deep roots in glycoscience and over 2,000 successful projects, we support pharmaceutical innovators from route scouting to late-stage clinical supply.

Our strength lies in combining high-purity synthesis with expert process development — always guided by precision, flexibility, and quality. ISO 9001 certified and Swissmedic compliant, we deliver value-based solutions that scale, adapt, and accelerate your path to market."

Dr. Arthur Bodenmüller

CEO & Founder

"Founded in 2000, SynphaBase has grown from an academic spin-off into a trusted Swiss CDRO specializing in complex carbohydrate synthesis. With deep roots in glycoscience and over 2,000 successful projects, we support pharmaceutical innovators from route scouting to late-stage clinical supply.

Our strength lies in combining high-purity synthesis with expert process development — always guided by precision, flexibility, and quality. ISO 9001 certified and Swissmedic compliant, we deliver value-based solutions that scale, adapt, and accelerate your path to market."

Contact us

What our customers say

Shiri Zemer-Goft

Senior Director

89bio (Member of Roche Group)

"Synphabase has talented scientists with deep expertise in the field of carbohydrate chemistry. We were able to utilize their experience, in combination with the capability to design new routes, and make first Kg amounts in a relatively short time enabling advanced drug development activities."

Dr. M Stohlmeier

Senior Product Manager

Chemie Uetikon AG (now Seqens)

"The process description we received, based on the excellent laboratory development of SynphaBase and the approval on a pilot scale, could be scaled up quickly and easily in our devices. Since then, we have been producing the substance on a multi-ton scale with very high reproducibility in terms of yield and quality."

Martin Knüsel

Managing Director

Merck & Cie KmG

"We firmly believe that our collaboration with SynphaBase AG will continue to drive significant advancements in carbohydrate synthesis, ultimately contributing to our shared goal of improving global health outcomes. Thank you, Synphabase AG, for your invaluable partnership."

Shiri Zemer-Goft

Senior Director

89bio (Member of Roche Group)

"Synphabase has talented scientists with deep expertise in the field of carbohydrate chemistry. We were able to utilize their experience, in combination with the capability to design new routes, and make first Kg amounts in a relatively short time enabling advanced drug development activities."

Dr. M Stohlmeier

Senior Product Manager

Chemie Uetikon AG (now Seqens)

"The process description we received, based on the excellent laboratory development of SynphaBase and the approval on a pilot scale, could be scaled up quickly and easily in our devices. Since then, we have been producing the substance on a multi-ton scale with very high reproducibility in terms of yield and quality."

Martin Knüsel

Managing Director

Merck & Cie KmG

"We firmly believe that our collaboration with SynphaBase AG will continue to drive significant advancements in carbohydrate synthesis, ultimately contributing to our shared goal of improving global health outcomes. Thank you, Synphabase AG, for your invaluable partnership."

Contact us

Frequently Asked Questions

Contact us

Our Values

DRIVEN BY RESULTS

We measure our success by the value we create for our clients. Every project is approached with focus, efficiency, and a commitment to delivering high-impact outcomes — from lab-scale to clinical supply.

POWERED BY PEOPLE

Our strength lies in our people. We harness individual expertise, foster collaboration, and create an environment where trust, ownership, and continuous growth drive innovation.

UNITED BY PURPOSE

We are bound by a shared mission: to enable meaningful medicines through glycoscience. This common purpose shapes our decisions, fuels our dedication, and connects our work to a greater good.

DRIVEN BY RESULTS

We measure our success by the value we create for our clients. Every project is approached with focus, efficiency, and a commitment to delivering high-impact outcomes — from lab-scale to clinical supply.

POWERED BY PEOPLE

Our strength lies in our people. We harness individual expertise, foster collaboration, and create an environment where trust, ownership, and continuous growth drive innovation.

UNITED BY PURPOSE

We are bound by a shared mission: to enable meaningful medicines through glycoscience. This common purpose shapes our decisions, fuels our dedication, and connects our work to a greater good.

Contact us

Contact us

We are happy to hear from you. Reach us directly via phone or email.

Olaf Bartram

Manager Marketing & Business Development

+41 61 827 79 00

o.bartram@synphabase.ch

Our Location

Güterstrasse 82 • 4133 Pratteln • Switzerland